Stay updated with breaking news from Herberta Fritsche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce that it has executed a
2023 News Releases Jan 11 2023 GHG Executes Binding LOI with Apollon Formularies Jan 4 2023 GHG Provides update ... | January 11, 2023
Apollon Formularies Plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange is pleased to announce that its medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures in third party independent laboratory testing. ¹ This finding is in addition to the results recently announced on May 18, 2021² that Apollon formulations were successful in killing HER2+ breast cancer cells, and the announcement on...
Apollon Formulations Kill Triple-Negative Breast Cancer (TNBC) Cells Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on Aquis Stock Exchange, is pleased to announce that its proprietary medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) cells in 3D cell cultures in third party independent laboratory testing. This finding is in addition to the results recently announced on May 18, 2021, that Apollon formulations were successful in killing HER2+ breast cancer cel...
Breast Cancer Cells Through Multiple Pathways LONDON/TORONTO, Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION, "Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cel...